A Controlled Multi-Centre Study of Hygroton® in the Treatment of Angina Pectoris

1977 ◽  
Vol 5 (6) ◽  
pp. 87-93
Author(s):  
J Bennion-Pedley ◽  
J F Donald ◽  
D F Ingram ◽  
R Million ◽  
J Seldrup
Keyword(s):  
Attack Rate ◽  
Adrenergic Receptor ◽  
Anginal Attack ◽  
Double Blind ◽  
Multi Centre Study ◽  
Matching Placebo ◽  
Different Types ◽  
Blind Comparison ◽  
Advantageous Effect ◽  
Better Than

Following the reports of Floyd (1966) and Floyd & Domenet (1972) a study was conducted on the effect of adding 50 mg of chlorthalidone ( Hygroton®) or a matching placebo to the usual antianginal regime of 25 patients. The study was a double blind comparison between chlorthalidone 50 mg tablets and a matching placebo; each patient received both treatments. Chlorthalidone was found to be significantly better than placebo in both reducing the incidence of attacks and the consumption of glyceryl trinitrate. Chlorthalidone reduced the day-time anginal attack rate by 38% as compared with the placebo attack rate. This improvement is of the same order as that achieved by beta-adrenergic receptor blocking agents in similar types of trial. A marked variation in response was found between different types of patients. The earlier investigations with diuretics in angina are reviewed, and a possible explanation for the advantageous effect of chlorthalidone is offered.

A Double-Blind Comparison of Three Times Daily and Single Night Dosage of the Tricyclic Anti-Depressant Dothiepin

1974 ◽  
Vol 2 (1) ◽  
pp. 12-19 ◽  
Author(s):  
J B Pearce ◽  
W Linford Rees
Keyword(s):  
Single Dose ◽  
Dosage Regimen ◽  
Trial Design ◽  
Double Blind Trial ◽  
Double Blind ◽  
Matching Placebo ◽  
Symptoms Of Depression ◽  
Daily Dosage Regimen ◽  
Single Night ◽  
Blind Comparison

The study here presented was designed to evaluate the advantages of a once a day dosage of tricyclic anti-depressants as against a thrice daily dosage regimen using dothiepin (Prothiaden) and matching placebo capsules in a group comparative double-blind trial design. A total of sixty-two patients were admitted to the trial and were randomly allocated to one or other of the dosage regimes. Patients were assessed weekly for five weeks. More favourable results were achieved with patients taking the single dose nocturnally which was well tolerated in addition to being effective in relieving symptoms of depression. A number of possible advantages of this method of administration are discussed.

Butacote and Brufen in the Treatment of Rheumatic Diseases. A Multi-Centre Study of Effectiveness and Tolerability

1974 ◽  
Vol 2 (2) ◽  
pp. 115-124 ◽  
Author(s):  
R G Regalado ◽  
P D Fowler
Keyword(s):  
General Practice ◽  
Morning Stiffness ◽  
Double Blind Trial ◽  
Double Blind ◽  
Multi Centre Study ◽  
Rheumatic Conditions ◽  
Enteric Coated ◽  
Inflammatory Polyarthritis ◽  
Better Than ◽  
Similar Incidence

A multi-centre double-blind trial in general practice compared Butacote (enteric-coated phenylbutazone) 300 mg daily, Brufen (ibuprofen) 1200 mg daily, and a placebo in the treatment of rheumatic conditions. Each patient received two of the three treatments for one month each. Twenty-nine doctors admitted 193 patients. 168 patients (sixty-four with inflammatory polyarthritis, and sixty-three with osteoarthrosis) completed the study, which showed that Butacote was significantly better than both Brufen and placebo for the relief of pain and morning stiffness, and improvement of function. Butacote was significantly preferred to both Brufen and placebo by patients and doctors, to placebo by the patients. Brufen was significantly better than placebo for relief of morning stiffness and for reducing the amount of supplementary analgesics. All three preparations were well tolerated and showed a similar incidence of gastric side-effects. It is concluded from this study that Butacote is more effective and as well tolerated as Brufen in the treatment of rheumatic conditions in general practice.

Multi-Centre Double-Blind Comparison of Terfenadine Once Daily versus Twice Daily in Patients with Hay Fever

1987 ◽  
Vol 15 (4) ◽  
pp. 212-223 ◽  
Author(s):  
S. Henauer ◽  
L. Hugonot ◽  
R. Hugonot ◽  
A. Kurzeja ◽  
H. Gastpar ◽  
...  
Keyword(s):  
Visual Analogue Scale ◽  
Analogue Scale ◽  
Rating Scale ◽  
Hay Fever ◽  
Similar Degree ◽  
Double Blind ◽  
Multi Centre Study ◽  
Once Daily ◽  
Point Rating Scale ◽  
Blind Comparison

This double-blind, randomized multi-centre study was designed to compare efficacy and tolerability of 120 mg terfenadine taken once daily (in the morning) with the established regimen of 60 mg terfenadine taken twice daily in the treatment of seasonal rhinitis. Two comparable groups, a total of 191 hay fever patients, were treated for 1 week. Symptom severity was assessed by the investigators before and at the end of the treatment (visual analogue scale), and daily by the patient (four-point rating scale). All symptoms improved to a similar degree in both groups. Differences between the two groups were not statistically significant, except for nasal symptoms in three cases as assessed by the visual analogue scale in one centre (better relief in the group given 120 mg terfenadine once daily). Tolerability was good and similar in both groups. The data presented show that in the treatment of hay fever 120 mg terfenadine given once daily is an effective, convenient and well tolerated alternative to the regimen of 60 mg terfenadine given twice daily.

A Double-Blind Comparison of Ibuprofen, ASA-Codeine-Caffeine Compound and Placebo in the Treatment of Dental Surgery Pain

1981 ◽  
Vol 9 (4) ◽  
pp. 257-260 ◽  
Author(s):  
D J P Squires ◽  
E L Masson
Keyword(s):  
Clinical Trial ◽  
Side Effects ◽  
Oral Dose ◽  
Codeine Phosphate ◽  
Double Blind ◽  
Dental Surgery ◽  
Caffeine Citrate ◽  
Blind Comparison ◽  
Almost All ◽  
Better Than

A double-blind randomized clinical trial was conducted in eighty-seven patients with mild, moderate or severe dental surgery pain to evaluate the analgesic activity of a single oral dose of the following compounds: (i) ibuprofen 400 mg, (ii) ACC-30 (a compound containing ASA 375 mg; codeine phosphate 30 mg; caffeine citrate 30 mg), (iii) placebo. Ibuprofen was significantly better than ACC-30 and placebo on almost all pain intensity, degree of relief and duration of analgesia parameters. ACC-30 was not significantly different from placebo on any analgesic measurement. No serious side-effects were reported with any of the study medications.

Sign in / Sign up

Export Citation Format

Share Document